Robert Ford on CGM market
From Abbott Laboratories ($ABT) Q1 2026 Earnings Call · · Castify Earnings Call
“I'm very bullish on this market. If I look at the big picture here, I'm very bullish on the CGM market as you know, Larry, I've always been and I continue to be. If I look at our assessment of the amount of people that should be on a CGM on a global basis, we estimate between 70 to 80 million people on CGMs should be. And obviously, there are different types of patients in that number, but overall, 70 to 80 million people. I think the market today is around 10 to 12.”
On , Robert Ford, Chairman, President & CEO at Abbott Laboratories, spoke about CGM market during Abbott Laboratories ($ABT) Q1 2026 Earnings Call on Castify Earnings Call.
About Robert Ford
On Abbott's first-quarter 2026 earnings call, Robert Ford stated he remains "very confident" in an acceleration of growth in the second half of the year, saying the company knows "what the drivers are" and is "laser focused" on execution. Ford described the integration of Exact Sciences as going "very well" and expressed optimism about the continuous glucose monitoring (CGM) market, estimating that 70 to 80 million people globally should be using CGMs compared to a current market of around 10 to 12 million. He also said he expects proposed language for CMS type 2 non-insulin coverage "coming soon," which he said would add coverage for close to 10 million people. Regarding Abbott's nutrition business, Ford said he would not make a long-term strategic decision based on near-term challenges and that his focus is on returning the business to its prior growth rate. He described the company as "very diversified" and noted that while it would be "great" for every business to beat expectations, that does not always happen. Ford also said the electrophysiology market is expected to grow in the "mid to high teens" and that Abbott is "shooting to do better than that."